[
  {
    "ts": null,
    "headline": "Merck in Talks to Buy Revolution Medicines for Around $30 Billion",
    "summary": "Merck  is in talks to acquire  Revolution Medicines  in a deal that could value it at around $30 billion, according to people familiar with the matter.  A deal for the cancer-drug biotech could come as soon as later this month, the people said, cautioning the talks could still fall apart or another suitor could prevail.  Merck has been discussing a deal valued between $28 billion and $32 billion, the people added.",
    "url": "https://finnhub.io/api/news?id=372dfaefbc806ee2a44388550c6fdff2219dd6d6fd1129af613cd5e316feed18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767988680,
      "headline": "Merck in Talks to Buy Revolution Medicines for Around $30 Billion",
      "id": 138052272,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Merck  is in talks to acquire  Revolution Medicines  in a deal that could value it at around $30 billion, according to people familiar with the matter.  A deal for the cancer-drug biotech could come as soon as later this month, the people said, cautioning the talks could still fall apart or another suitor could prevail.  Merck has been discussing a deal valued between $28 billion and $32 billion, the people added.",
      "url": "https://finnhub.io/api/news?id=372dfaefbc806ee2a44388550c6fdff2219dd6d6fd1129af613cd5e316feed18"
    }
  },
  {
    "ts": null,
    "headline": "What Catalysts Could Shift AbbVie’s Story As Analysts Rework Targets And Drug Expectations",
    "summary": "AbbVie’s latest valuation update comes with only a marginal trim to its fair value estimate, shifting from about US$244.68 to roughly US$244.56 per share, even as analysts reassess the story around its key drug franchises. The discount rate and long term revenue growth assumptions have been tweaked only slightly, reflecting how bullish and bearish views are being fine tuned rather than completely rewritten as new research lands. Read on to see how you can keep on top of these small but...",
    "url": "https://finnhub.io/api/news?id=0f47b28c5c11f5b8040f208f7e3ca14857ad8bc5b2ab0b046a50383f349fc428",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767986086,
      "headline": "What Catalysts Could Shift AbbVie’s Story As Analysts Rework Targets And Drug Expectations",
      "id": 138052273,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie’s latest valuation update comes with only a marginal trim to its fair value estimate, shifting from about US$244.68 to roughly US$244.56 per share, even as analysts reassess the story around its key drug franchises. The discount rate and long term revenue growth assumptions have been tweaked only slightly, reflecting how bullish and bearish views are being fine tuned rather than completely rewritten as new research lands. Read on to see how you can keep on top of these small but...",
      "url": "https://finnhub.io/api/news?id=0f47b28c5c11f5b8040f208f7e3ca14857ad8bc5b2ab0b046a50383f349fc428"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 11",
    "summary": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 11",
    "url": "https://finnhub.io/api/news?id=24cd194a3a20b8e0867da9447639c2a8763dc564d568cdccc20d2e295e9e3b46",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767981556,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 11",
      "id": 138050125,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=24cd194a3a20b8e0867da9447639c2a8763dc564d568cdccc20d2e295e9e3b46"
    }
  },
  {
    "ts": null,
    "headline": "2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio",
    "summary": "Add some stability to your holdings with these healthcare giants.",
    "url": "https://finnhub.io/api/news?id=f9da08e5e2a8b2b0eb10caa1a88927bea2c28de4bdc041de0fdf50896272f3b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767978300,
      "headline": "2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio",
      "id": 138052220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Add some stability to your holdings with these healthcare giants.",
      "url": "https://finnhub.io/api/news?id=f9da08e5e2a8b2b0eb10caa1a88927bea2c28de4bdc041de0fdf50896272f3b6"
    }
  },
  {
    "ts": null,
    "headline": "Merck in Talks to Buy Revolution Medicines Per Financial Times Report",
    "summary": "Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.",
    "url": "https://finnhub.io/api/news?id=f05e59868fa739ee42389cc26db146320c9f472915c165f090611956c9b051c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767978180,
      "headline": "Merck in Talks to Buy Revolution Medicines Per Financial Times Report",
      "id": 138052275,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.",
      "url": "https://finnhub.io/api/news?id=f05e59868fa739ee42389cc26db146320c9f472915c165f090611956c9b051c6"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
    "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
    "url": "https://finnhub.io/api/news?id=06215b717963945c9963b8a712e672df556fb394ab6ba879e3642747690c939a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767975542,
      "headline": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
      "id": 138052209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
      "url": "https://finnhub.io/api/news?id=06215b717963945c9963b8a712e672df556fb394ab6ba879e3642747690c939a"
    }
  },
  {
    "ts": null,
    "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
    "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
    "url": "https://finnhub.io/api/news?id=8a744dad378981948ddd9bbf5a218db486800ed8d38efd33667ffd0ec67117ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767973860,
      "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
      "id": 138052210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
      "url": "https://finnhub.io/api/news?id=8a744dad378981948ddd9bbf5a218db486800ed8d38efd33667ffd0ec67117ca"
    }
  },
  {
    "ts": null,
    "headline": "Revolution Medicines: \"Strong Buy\" As Acquisition Prospects Continue To Circle",
    "summary": "RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest analysis on the stock here.",
    "url": "https://finnhub.io/api/news?id=5392b16095136b8b34c52c3aea98faf5f617421865c392bbc1efc69e3891d891",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767969206,
      "headline": "Revolution Medicines: \"Strong Buy\" As Acquisition Prospects Continue To Circle",
      "id": 138049147,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2248270095/image_2248270095.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest analysis on the stock here.",
      "url": "https://finnhub.io/api/news?id=5392b16095136b8b34c52c3aea98faf5f617421865c392bbc1efc69e3891d891"
    }
  },
  {
    "ts": null,
    "headline": "Here's What We Expect From AbbVie's Immunology Segment in Q4",
    "summary": "ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.",
    "url": "https://finnhub.io/api/news?id=09b911cafe130d129e73462fa37b066d995c4dce1085f38c82dc1a5f6a7d8e29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767962640,
      "headline": "Here's What We Expect From AbbVie's Immunology Segment in Q4",
      "id": 138045462,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.",
      "url": "https://finnhub.io/api/news?id=09b911cafe130d129e73462fa37b066d995c4dce1085f38c82dc1a5f6a7d8e29"
    }
  },
  {
    "ts": null,
    "headline": "HSBC lists 11 potential U.S. outperformers heading into earnings",
    "summary": "Investing.com -- HSBC has identified 11 U.S. stocks that could outperform as the fourth-quarter earnings season begins, highlighting companies with strong competitive positions, improving fundamentals and exposure to long-term themes.",
    "url": "https://finnhub.io/api/news?id=983d3d6c8707e8d88a1c351006017098b04fad71beb43cb0151e6547efb9c3fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767961731,
      "headline": "HSBC lists 11 potential U.S. outperformers heading into earnings",
      "id": 138045471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com -- HSBC has identified 11 U.S. stocks that could outperform as the fourth-quarter earnings season begins, highlighting companies with strong competitive positions, improving fundamentals and exposure to long-term themes.",
      "url": "https://finnhub.io/api/news?id=983d3d6c8707e8d88a1c351006017098b04fad71beb43cb0151e6547efb9c3fc"
    }
  },
  {
    "ts": null,
    "headline": "Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges.",
    "summary": "Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug biotech for up to $32 billion.",
    "url": "https://finnhub.io/api/news?id=71454e56cb8644c903271ec6f79902ea0eda92156b6fd9c59654511c1c549385",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767956040,
      "headline": "Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges.",
      "id": 138045485,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug biotech for up to $32 billion.",
      "url": "https://finnhub.io/api/news?id=71454e56cb8644c903271ec6f79902ea0eda92156b6fd9c59654511c1c549385"
    }
  },
  {
    "ts": null,
    "headline": "Is AbbVie (ABBV) Still Attractive After Strong 1-Year And 5-Year Share Price Gains?",
    "summary": "If you are wondering whether AbbVie at around US$224 per share still offers value, or if most of the opportunity is already priced in, this article is for you. The stock is roughly flat over the last month with a 0.5% return, but that sits alongside a 30.0% return over 1 year and 141.2% over 5 years, which can change how investors think about both risk and potential reward. Recent headlines have focused on AbbVie’s position as a major US pharmaceuticals and biotech player and how its...",
    "url": "https://finnhub.io/api/news?id=a2073342eef29a9f808feea6ce08401094eeb777071e0535f5c24080337625b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767946388,
      "headline": "Is AbbVie (ABBV) Still Attractive After Strong 1-Year And 5-Year Share Price Gains?",
      "id": 138044523,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "If you are wondering whether AbbVie at around US$224 per share still offers value, or if most of the opportunity is already priced in, this article is for you. The stock is roughly flat over the last month with a 0.5% return, but that sits alongside a 30.0% return over 1 year and 141.2% over 5 years, which can change how investors think about both risk and potential reward. Recent headlines have focused on AbbVie’s position as a major US pharmaceuticals and biotech player and how its...",
      "url": "https://finnhub.io/api/news?id=a2073342eef29a9f808feea6ce08401094eeb777071e0535f5c24080337625b1"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures: Jobs Data, Trump Tariffs Ruling Loom After Small Caps Lead",
    "summary": "Small caps hit a new high Thursday as techs faltered. The December jobs report a possible Trump tariffs ruling loom Friday.",
    "url": "https://finnhub.io/api/news?id=4ddf1005a42686e66ff4d4b13a65f6cb85e512d0035656395f7a3bcee5e598f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767929114,
      "headline": "Dow Jones Futures: Jobs Data, Trump Tariffs Ruling Loom After Small Caps Lead",
      "id": 138042898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Small caps hit a new high Thursday as techs faltered. The December jobs report a possible Trump tariffs ruling loom Friday.",
      "url": "https://finnhub.io/api/news?id=4ddf1005a42686e66ff4d4b13a65f6cb85e512d0035656395f7a3bcee5e598f0"
    }
  },
  {
    "ts": null,
    "headline": "Wolfe Research Downgrades AbbVie (ABBV)",
    "summary": "Wolfe Research Downgrades AbbVie (ABBV)",
    "url": "https://finnhub.io/api/news?id=6d727101b519273c84a806d3efa3fc3ede5d8bee7c12bcbc077ed2ab41fc3220",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767917074,
      "headline": "Wolfe Research Downgrades AbbVie (ABBV)",
      "id": 138040912,
      "image": "",
      "related": "ABBV",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6d727101b519273c84a806d3efa3fc3ede5d8bee7c12bcbc077ed2ab41fc3220"
    }
  }
]